Leerink Partnrs Has Bearish Outlook for AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Leerink Partnrs decreased their Q1 2025 earnings estimates for Axsome Therapeutics in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($1.35) per share for the quarter, down from their previous forecast of ($1.31). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.77) EPS, FY2028 earnings at $8.60 EPS and FY2029 earnings at $15.05 EPS.

Other analysts have also recently issued research reports about the stock. Leerink Partners upped their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday, February 10th. Mizuho raised their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research report on Thursday, March 27th. Morgan Stanley boosted their price objective on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Axsome Therapeutics in a report on Thursday, April 3rd. Finally, Wells Fargo & Company upped their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $169.80.

Axsome Therapeutics Trading Down 0.6 %

NASDAQ:AXSM traded down $0.65 during mid-day trading on Wednesday, hitting $103.81. The company had a trading volume of 252,974 shares, compared to its average volume of 678,618. The firm has a market cap of $5.06 billion, a P/E ratio of -17.33 and a beta of 0.88. The business's fifty day moving average is $118.16 and its two-hundred day moving average is $102.54. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 22.40% of the company's stock.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds have recently made changes to their positions in the stock. NBC Securities Inc. acquired a new position in Axsome Therapeutics in the 1st quarter worth about $31,000. Raiffeisen Bank International AG acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $51,000. Assetmark Inc. bought a new position in Axsome Therapeutics in the 4th quarter valued at approximately $52,000. R Squared Ltd acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $64,000. Finally, Aquatic Capital Management LLC bought a new stake in Axsome Therapeutics during the 4th quarter worth approximately $76,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.